Read More Pharma Industry News Vesper Bio reports 95% CSF progranulin boost in FTD-GRN trial—what’s next for VES001? Vesper Bio’s oral FTD therapy VES001 boosts CSF progranulin by 95%. Explore what this means for dementia prevention and future clinical milestones. bySrinathOctober 31, 2025